The drug would be the only one approved for the roughly 12,000 to 20,000 PWS patients with hyperphagia in the United States. But even if the Redwood City company's (Nasdaq: SLNO) drug is approved ...

The drug, branded as Vykat XR, treats hyperphagia, an overriding desire to eat, in patients with Prader Willi Syndrome, or PWS. The once-a-day tablet — the only drug approved for the 12,000 to ...

Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults. Per the PWS Association USA, approximately one in ...

March 27, 2025 – The FDA has approved a drug to treat a key symptom of a rare life-threatening genetic disorder known as Prader-Willi syndrome (PWS) in adults and children ages 4 or older.

Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder Prader-Willi Syndrome (PWS), several companies have come up short in their ...

Affecting an estimated one in every 15,000 newborns in the US, PWS is caused by an abnormality in the gene expression on chromosome 15. The disorder results in a wide range of physical, mental and ...